Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
QURE Stock Chart & Stats
$23.43
-$1.39(-7.88%)
At close: 4:00 PM EST
$23.43
-$1.39(-7.88%)
Day’s Range― - ―
52-Week Range$7.76 - $71.50
Previous CloseN/A
Volume1.49M
Average Volume (3M)1.92M
Market Cap
$1.34B
Enterprise Value$913.71M
Total Cash (Recent Filing)$694.25M
Total Debt (Recent Filing)$66.16M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 02, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding61,603,770
10 Day Avg. Volume2,097,156
30 Day Avg. Volume1,919,083
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-127.24
Price to Sales (P/S)31.68
P/FCF Ratio-4.62
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue58.01
Enterprise Value/Gross Profit65.82
Enterprise Value/Ebitda-6.25
Forecast
1Y Price Target
$48.17Price Target Upside105.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Enzyme ExpressionUpdated clinical results show dose-dependent, durable increases in the therapeutic enzyme for Fabry disease, supporting a sustained biological effect that strengthens confidence in the program.
Pipeline Diversification And Financial FlexibilityProgress across central nervous system and metabolic programs, together with a strong balance sheet, preserves strategic optionality to pursue multiple regulatory or development strategies.
Therapy-sparing Clinical BenefitSeveral treated patients were able to discontinue enzyme replacement therapy while maintaining stable disease biomarkers, indicating meaningful clinical benefit and a potential reduction in long-term treatment burden.
Bears Say
Competitive Filing And Data TransparencyA competitor's regulatory submission combined with limited disclosure of certain kidney-function data increases competitive and regulatory pressure and could negatively affect market positioning.
Regulatory Acceptance RiskFDA feedback that current single-arm Phase 1/2 data may not be sufficient for approval raises the prospect that additional confirmatory studies or alternative evidence will be required, prolonging timelines.
Safety And Dosing InterruptionsDose-limiting toxicities and liver enzyme elevations prompted pauses in higher-dose cohorts, creating safety and dose-selection risks that could delay development.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $7.76 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $1.34B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Mar 02, 2026 which is in 11 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Nov 10, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.903 by -$0.477.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.93.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 61,603,770 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.903. Following the earnings report the stock price went down -5.901%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.17 (105.59% Upside)
$48.17 (105.59% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.71%
12-Months-Change
Fundamentals
Return on Equity
-165.27%
Trailing 12-Months
Asset Growth
37.56%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showcased significant advancements in uniQure's therapeutic pipeline, particularly for Huntington's disease and epilepsy, despite regulatory challenges and increased operational costs. The financial position remains strong, supporting future operations. However, setbacks with the FDA's stance on AMT-130 and the pause in the AMT-162 program posed challenges.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$48.17
▲(105.59% Upside)
Technical Analysis
Ownership Overview
2.20% Insiders
20.78% Mutual Funds
7.71% Other Institutional Investors
61.19% Public Companies and Individual Investors